Saturday 17 October 2026 Export RLAY’s income statement to Excel — free account

Relay Therapeutics, Inc.

In the quarter to June 2026, revenue fell 95.4%, EPS was flat and free cash flow grew 2.13%, each against the same quarter a year earlier.

16.28 1.02 −5.90%

Follow RLAY

Alert me

Market cap: $3.8B
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 5/9
Altman Z: 10.99
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 129.54

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	4	—	1	4	1	3	6	4	3	2

Insider Ownership 15.38%

Capital & Financial Ratios $m

Market Cap 3,790.00

Revenue 11.03

Net Income (286.04)

Free Cash Flow (212.20)

Net Debt (910.93)

Current Ratio 18.27

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.66)

P/S ratio 299.51

P/B ratio 3.71

Past 5Y EPS Growth —

This Y EPS Growth 0.53%

Next Y EPS Growth (0.55%)

Next Y revenue growth (27.32%)

Next 5Y EPS Growth (0.26%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 59.35%

10-year low 10-year high

P/B against its own 10 years 75.31%

10-year low 10-year high

EV/Sales against its own 10 years 51.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	750	781	555	911
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	11	6	8
	770	809	578	928

	2023	2024	2025	Q'26
Payables	9	14	8	11
ST’ Debt	—	—	—	—
Other	1	2	0	1
	30	51	26	51

Compound Annual Growth %

	10y	5y	3y
Sales	—	(28.58%)	123.20%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(5.77%)	(15.81%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	0	—	—	—
’25	8	1	—	7	15
’24	10	—	—	—	10
’23	0	0	25	0	26
’22	0	0	0	0	1
’21	1	1	1	1	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(51)	(54)	—	—	—
’25	(73)	(55)	(62)	(45)	(235)
’24	(50)	(66)	(75)	(58)	(249)
’23	(67)	(69)	(75)	(89)	(300)
’22	(49)	(57)	(66)	(57)	(229)
’21	47	(28)	(53)	(40)	(74)
’20	(22)	(21)	(24)	(35)	(102)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(51)	(54)	—	—	—
’25	(74)	(55)	(62)	(45)	(236)
’24	(52)	(66)	(75)	(58)	(251)
’23	(69)	(70)	(76)	(89)	(304)
’22	(52)	(59)	(68)	(59)	(239)
’21	46	(29)	(55)	(41)	(78)
’20	(23)	(21)	(24)	(35)	(104)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.41)	(0.41)	—	—	—
’25	(0.46)	(0.41)	(0.43)	(0.32)	(1.61)
’24	(0.62)	(0.69)	(0.63)	(0.45)	(2.36)
’23	(0.78)	(0.81)	(0.54)	(0.67)	(2.79)
’22	(0.57)	(0.71)	(0.76)	(0.56)	(2.59)
’21	(0.47)	(2.10)	(0.66)	(0.62)	(3.82)
’20	(5.99)	(6.06)	(0.51)	11.33	(1.23)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	32.56	25.72	12.65	5.95	4.01	1.78	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	57.59	64.37	35.36	23.18	12.14	9.04
People
People	Employees	—	—	—	122	159	245	327	323	261	192
	Revenue/emp, $m	—	—	—	0.00	0.52	0.01	0.00	0.08	0.04	0.08
Income, $m
Income, $m	Revenue	—	—	—	—	83	3	1	26	10	15
	Gross margin, %	—	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(49)	(75)	(52)	(364)	(291)	(342)	(338)	(276)
	EBT margin, %	—	—	0.00	0.00	(63.41)	(12,012.94)	(21,036.13)	(1,338.66)	(3,374.72)	(1,800.58)
	Net income	—	0	(49)	(75)	(52)	(364)	(291)	(342)	(338)	(276)
	Depreciation	—	—	2	0	3	6	5	(5)	(7)	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	1.94	0.03	0.01	0.21	0.07	0.09
	Earnings	—	—	(0.54)	(21.82)	(0.59)	(3.82)	(2.59)	(2.79)	(2.36)	(1.61)
	Cash flow	—	—	(0.49)	(19.16)	(2.40)	(0.78)	(2.04)	(2.45)	(1.74)	(1.37)
	Capex	—	—	0.00	(2.31)	(0.05)	(0.04)	(0.08)	(0.03)	(0.01)	0.00
	Free cash flow	—	—	(0.49)	(21.48)	(2.45)	(0.82)	(2.13)	(2.48)	(1.76)	(1.37)
	Book value	—	—	4.68	(52.29)	17.91	9.44	8.47	6.13	5.44	3.30
	Shares, m	—	—	90	3	43	95	112	123	143	172
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	964.56	1,222.30	56.91	16.66	57.24
	P/B	—	—	—	—	2.32	3.25	1.78	1.93	0.76	2.56
	EV/Sales	—	—	—	—	0.00	648.26	498.97	27.55	(5.45)	35.37
	EV/FCF	—	—	—	—	(10.47)	(25.21)	(2.89)	(2.31)	0.77	(3.80)
Cash, $m
Cash, $m	Operating cash flow	—	—	(44)	(66)	(102)	(74)	(229)	(300)	(249)	(235)
	Capex	—	—	(2)	(8)	(2)	(3)	(9)	(4)	(2)	0
	Free cash flow	—	—	(44)	(74)	(104)	(78)	(239)	(304)	(251)	(236)
Balance, $m
Balance, $m	Working capital	—	—	417	349	756	952	956	740	758	553
	Total debt	—	—	0	25	25	23	57	—	—	—
	Net debt	—	—	(422)	(356)	(678)	(958)	(999)	(750)	(781)	(555)
	Shareholders’ equity	—	—	421	(180)	763	898	950	752	778	567
Returns, %
Returns, %	ROA	—	—	(22.74)	(18.32)	(38.60)	(40.25)	(27.56)	(35.19)	(39.38)	(37.05)
	ROIC	—	—	0.00	0.00	(40.91)	0.00	0.00	(12,160.29)	0.00	(1,508.62)
	ROE	—	—	33.53	51.68	(78.99)	(43.81)	(31.44)	(40.18)	(44.15)	(41.12)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EWTX Edgewise Therapeutics, Inc.	$4.2B	— (loss-making)	—	—	n/m	−30.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ABCL AbCellera Biologics Inc.	$4.1B	— (loss-making)	— (loss-making)	−76.29% (below 0%: shrinking)	n/m	+151.98% (above 0%: growing)	100.00%	(1,550.05%)	Compare
LEGN Legend Biotech Corporation Sponsored ADR	$3.8B	— (loss-making)	112×	+51.90% (above 0%: growing)	n/m	−26.79% (below 0%: shrinking)	64.54%	14.37%	Compare
TNGX Tango Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%	Compare
RLAY Relay Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	+69.41% (above 0%: growing)	n/m	+288.08% (above 0%: growing)	93.03%	(11.45%)	Compare
VKTX Viking Therapeutics, Inc.	$3.5B	— (loss-making)	—	—	n/m	−165.98% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$3.7B	—	—	+51.90%	—	−15.69%	64.54%	0.00%

All 614 Biotechnology stocks →

Relay Therapeutics, Inc. (RLAY) key facts

Relay Therapeutics, Inc. (RLAY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RLAY traded at $16.28, a market capitalization of $3.8 billion.
Return on equity was −41.1% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 10.99 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.